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Abstract: Background: 
Maternal pertussis immunisation was introduced during the pertussis 
resurgence in England in 2012 as a temporary measure to protect infants 
too young to be vaccinated. The programme was shown to be safe and highly 
effective. However, continuation of maternal vaccination as a routine 
programme requires a cost effectiveness analysis.  
 
Method: 
The estimated prevented disease burden among mothers and their infants 
was obtained assuming 89% (95% CI: 19%-99%) vaccine efficacy for mothers 
and 91% (95% CI: 84%-95%) for infants. Future incidence was projected 
based on the disease rates in 2010-2012, including the four-year cycle of 
low and high incidence years. Full probabilistic sensitivity analysis was 
performed for different scenarios. 
 
Results: 
Assuming a vaccine coverage of 60%, there were 1650 prevented 
hospitalisations in infants (3.5% discounting, the first 10 years), 
including 55-60 deaths and ~20,500 cases among mothers, of which around 
1800 would be severe. The annual costs of the programme are £7.3 million 
assuming a price of £10 per dose and £9.4 million assuming £15 per dose. 
Using discounting of 3.5%, a 200 year time horizon and a price of £10 per 
dose (+ £7.5 administration costs) only 25% of the iterations were below 
£30,000 per QALY. Using a 35% higher incidence resulted in 88% of the 
scenarios below this threshold.  Assuming that the incidence remains at 
the level at the height of 2012, then the programme would be highly cost 
effective, with an ICER of £16,865 (£12,209-£25,976; price of £10 and 
3.5%/3.5% discounting). 
 
Conclusion: 
Maternal vaccination is effective in preventing severe illness and deaths 
in infants but the cost-effectiveness of the programme is highly 
dependent on future incidence which is necessarily uncertain. However, 
the duration and magnitude of protection against transmission afforded by 
the current acellular vaccines is also uncertain as are the associated 
effects on future herd immunity. The direct protection offered by the 
maternal dose provides the only certain way of protecting vulnerable 
infants from birth.  
 
 
 
 
 
Dear Editor, 
 
The manuscript we present is on maternal pertussis vaccination; maternal vaccination was 
introduced in England to mitigate the observed increase in pertussis in 2012. The programme was 
initially introduced without much direct evidence, but was very effective.  
 
We present a cost-effectiveness study based on the observed incidence and vaccine-efficacy in 
England. The future incidence of pertussis is projected including cyclical patterns and both the 
impact on mother and child. This approach enabled to investigate relevant implications of different 
discount and time horizon scenarios, as well as the relevant uncertainty.   
 
However most importantly, as you will see in the discussion, the continuation of the programme, 
whose dramatic success in terms of infant cases and deaths prevented has galvanised global interest 
[see for example: 
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccines
andOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM474285.pdf) is 
threatened by being considered not cost effective. While the decision body in the UK (Joint 
Committee for Vaccination and Immunisation) has deferred the decision about discontinuing the 
programme for 5 years, as there was natural concern about letting infants die from a vaccine 
preventable disease based on cost effectiveness criteria alone. In our discussion we challenge the 
application of conventional incremental cost effectiveness analyses to this programme and highlight 
other very tangible benefits that accrue from its implementation. Moreover, the programme is cost 
effective in epidemic years which raises interesting questions about whether it is feasible to turn it 
on and off depending on incidence as is currently done with antivirals for influenza.  
 
As other countries are now actively promoting maternal pertussis immunisation but like the UK will 
need to consider cost effectiveness – even WHO through its Strategic Advisory Group of Experts 
requires cost effectiveness analyses to support its global recommendations. Ours is the first such 
analysis of an implemented programme and the methodological, practical, and ethical issues we 
identify are applicable for other countries and are likely to engender debate (and could be a suitable 
topic for a commentary).  
We therefore hope that you consider this manuscript for review in your journal. The manuscript is 
not submitted elsewhere. 
 
Yours sincerely, 
 
Albert Jan van Hoek (on behalf of the co-authors) 
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Background: 
Maternal pertussis immunisation was introduced during the pertussis resurgence in England in 2012 
as a temporary measure to protect infants too young to be vaccinated. The programme was shown 
to be safe and highly effective. However, continuation of maternal vaccination as a routine 
programme requires a cost effectiveness analysis.  
Method: 
The estimated prevented disease burden among mothers and their infants was obtained assuming 
89% (95% CI: 19%-99%) vaccine efficacy for mothers and 91% (95% CI: 84%-95%) for infants. Future 
incidence was projected based on the disease rates in 2010-2012, including the four-year cycle of 
low and high incidence years. Full probabilistic sensitivity analysis was performed for different 
scenarios. 
 
Results: 
Assuming a vaccine coverage of 60%, there were 1650 prevented hospitalisations in infants (3.5% 
discounting, the first 10 years), including 55-60 deaths and ~20,500 cases among mothers, of which 
around 1800 would be severe. The annual costs of the programme are £7.3 million assuming a price 
of £10 per dose and £9.4 million assuming £15 per dose. Using discounting of 3.5%, a 200 year time 
horizon and a price of £10 per dose (+ £7.5 administration costs) only 25% of the iterations were 
below £30,000 per QALY. Using a 35% higher incidence resulted in 88% of the scenarios below this 
threshold.  Assuming that the incidence remains at the level at the height of 2012, then the 
programme would be highly cost effective, with an ICER of £16,865 (£12,209-£25,976; price of £10 
and 3.5%/3.5% discounting). 
 
Abstract
Conclusion: 
Maternal vaccination is effective in preventing severe illness and deaths in infants but the cost-
effectiveness of the programme is highly dependent on future incidence which is necessarily 
uncertain. However, the duration and magnitude of protection against transmission afforded by the 
current acellular vaccines is also uncertain as are the associated effects on future herd immunity. 
The direct protection offered by the maternal dose provides the only certain way of protecting 
vulnerable infants from birth.  
 
Words: 319 
 Maternal pertussis vaccination is highly effective at preventing infant deaths  
 Its cost-effectiveness as an adjunct to paediatric vaccination needs evaluation  
 Future pertussis incidence is the major determinant of cost-effectiveness  
 The ability of acellular vaccines to control transmission is questionable  
 Given this uncertainty continuation of maternal immunisation is advisable 
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Introduction 1 
In October 2012 a maternal pertussis vaccination programme was introduced in England [1] as an 2 
outbreak measure in response to the highest number of infant cases and deaths from pertussis in 3 
more than a decade in 2012. All of the infants who died developed disease before they were eligible 4 
to receive the primary course of vaccine. The maternal programme has been well received in 5 
England, with uptake peaking at 60% and evidence of a direct impact in infants under 3 months of 6 
age [1]. 7 
Maternal vaccination is offered in every pregnancy, ideally between 28 and 32 weeks, but up to 38 8 
weeks [1] and works in two ways: by passive immunisation of the infant through the transport of 9 
antibodies across the placenta and by directly protecting the mother which lowers the probability of 10 
her being a source of infection to her infant. The programme effectiveness against infant disease has 11 
been estimated to be 91% (84%-95%) in England [1] Maternal vaccination thus offers a safe [2] and 12 
effective way  of directly protecting those too young to be vaccinated. 13 
Although this programme was introduced as a temporary outbreak response measure, the question 14 
now is whether, based on the evidence of effectiveness, maternal vaccination should be added to 15 
the routine programme in England. In the England, policy recommendations by the Joint Committee 16 
and Vaccination and Immunisation require evidence of cost effectiveness.  17 
In this paper we investigate the cost-effectiveness of introducing maternal vaccination programme 18 
into the national immunisation schedule, offering a dose to women in every pregnancy. 19 
  20 
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Methods 1 
Programme under consideration 2 
The programme under study in this analysis is vaccinating pregnant woman in the 3rdtrimester with 3 
one dose of a pertussis-containing vaccine designed for adult boosting. In practice, women will be 4 
offered vaccine at the first appointment in the 3rd trimester (week 28-32, where possible and up to 5 
38 weeks).  6 
Impact of the vaccine 7 
The duration and type of protection induced in the mother and infant differs. The infant is passively 8 
protected by maternal antibodies until development of active immunity following receipt of the first 9 
dose of pertussis-containing vaccine at 2 months of age. In this analysis disease up to three months 10 
of age was considered preventable by maternal vaccination assuming that those hospitalised 11 
between two and three months are either still unvaccinated, or were exposed before they could 12 
develop protective antibodies after the first dose of the primary course. Vaccinating the mother, will 13 
boost her pre-existing immunity which will afford protection for a longer time. This was assumed to 14 
be 5 years, based on estimates of the duration of protection after a 5th dose of acellular vaccine 15 
given around five years of age and antibody persistence after an adolescent acellular booster [3]. 16 
However, pertussis antibody titres rapidly decline within a year of boosting [4] and therefore vaccine 17 
is recommended  in each pregnancy, regardless of vaccine history in order to passively protect the 18 
infant. This means that some women will get pregnant again and receive the vaccine for a second 19 
time while still protected against disease. Therefore, to take this into account, the effective duration 20 
of maternal protection was reduced. Where vaccine recipients do not become pregnant again they 21 
enjoy five years of protection; when they do have a subsequent pregnancy an average interval 22 
between pregnancies was assumed of 3 years based on national maternity data [5]. For the analysis 23 
a weighted average duration was calculated based on the observed distribution of first, second, third 24 
 3 
 
and fourth pregnancies (see the online material for more detail). The average duration of protection 1 
was estimated as 3.89 years or 47 months.   2 
Therefore, for example, if a mother was vaccinated in the 5th month of the programme two months 3 
before delivery, disease in the mother would be on average prevented from month 5 until month 52 4 
and in the infant from month 7 until the end of month 9 of the programme.  5 
 6 
The preventable disease burden 7 
The transmission of pertussis is cyclical, with a 3-4 year interval between high transmission years. 8 
Due to the fluctuating disease burden the cost effectiveness of a dose will change over time within 9 
the cycle. Therefore the programme was evaluated over a longer period, using a fluctuating monthly 10 
incidence. The fluctuation was simulated by a sine-function with a peak every 4 years, oscillating 11 
between the maximum and minimum incidence.   12 
As the vaccine prevents both disease in the infant and the mother, separate estimates of the 13 
preventable disease burden were made. For infants under 3 months, the burden of disease was 14 
estimated from hospital admission data as pertussis at this age is severe and over 90% of cases  15 
require in-patient care [6]; it is also the most complete data source as admissions in infants under 3 16 
months are nearly double the number of notified cases in this age group [6]. In contrast, pertussis in 17 
adults is often a mild, unrecognised illness so notifications and laboratory confirmed cases will 18 
substantially underestimate the true burden of clinical illness; it is conservatively assumed that 19 
laboratory confirmed cases comprise only a third of all clinically significant pertussis illness in adults 20 
[7]. Evidence suggests that the source of infection for most infant pertussis cases is other family 21 
members [8] so it can be assumed that the exposure in mothers and infants is similar resulting  in a 22 
synchronised cyclical pattern of infection in both groups.  23 
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The future incidence of pertussis is uncertain given the recent resurgence in the UK  and some other 1 
countries, possibly associated with more rapid waning of immunity after immunisation with acellular 2 
than whole cell vaccine [3,9]. Several future incidence scenarios are therefore presented – a low, 3 
base case and a high incidence scenario. A low incidence scenario based on 75% of the cases 4 
observed in 2012, a base case scenario assuming outbreak sizes as observed in 2011-2012 and three 5 
high incidence scenarios, one with 35% more disease than in 2012 in the peak years, a second with 6 
35% higher incidence in the low years, and a third with both a higher incidence in the peaks and 7 
troughs. These incidence scenarios were used in combination with different scenarios on the time-8 
horizon and discounting. 9 
Disease outcomes 10 
Infants: 11 
The sine function was fitted using the overall incidence of hospitalised disease in infants under 3 12 
months between September 2010-September 2012. The incidence in the trough year was based on 13 
the observed number of hospitalised infant cases in 2010. 14 
Hospitalisation 15 
Infants were admitted to hospital and could have 1 day of admission, multiple days of admission 16 
without intensive care, multiple days with intensive care, and multiple days with intensive care and 17 
extracorporeal membrane oxygenation (ECMO), for a proportion of intensive care patients special 18 
transport was needed. 19 
The duration of admission and whether there was an admission to the paediatric intensive care unit 20 
(PICU) was based on the Hospital Episode Statistics (HES) for the period January 2007-February 2012, 21 
HES is a database that includes all hospital admissions in England [10] The admission rate to PICU is 22 
assumed to be the proportion of patients  who needed ventilation (procedure codes OPCS4 E85, 23 
E89, X58 and X52). The duration of admission to the PICU and whether ECMO or special transport 24 
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was needed was based on the Paediatric Intensive Care Audit Network (PICAnet) database (2006-1 
2012) which contains detailed information on PICU admissions.  2 
The costs were based on the NHS reference costs 2012-2013 [11], using PA65A (Non-elective Upper 3 
respiratory Tract Disorder £422 (£282-£523) for those admitted without an overnight stay and 4 
PA65B (Non-elective Long stay Upper respiratory Tract Disorder with complications; £758 (£552 – 5 
£885) per day) for non-ICU days in case of overnight stay and XB04Z (Pediatric Critical Care Intensive 6 
Basic Enhanced; £2,110 (£2,004-£2,130) per day) or XB01Z (Pediatric Critical Care Intensive – 7 
ECMO/ECLS; £4,391 (£3,966-£4,763) per day in case of PICU admission without or with ECMO 8 
respectively. 9 
Mortality 10 
Although previously it was suggested that the number of pertussis deaths were substantially 11 
underestimated [12], a more recent analysis showed that the reporting of deaths was consistent 12 
between various sources and that therefore the under reporting of recognised pertussis deaths in 13 
England is small [13]. There were 16 reported deaths due to pertussis in infants under 3 months of 14 
age born between 1 October 2011- 30 September 2012 (before the maternal programme was 15 
introduced) and a total of 513 reported hospitalisations in infants under 3 months in the same 16 
period giving a case fatality rate of 3.1% (95% CI: 1.75%-4.7%).  17 
The total utility loss for a fatal case was calculated based on the estimated life expectancy with a 18 
correction for the population norms of the quality of life by age. The life expectancy was based on 19 
the 2008-2010 mortality [14] and the population norms were obtained from a 2010 survey among 20 
22,166 adults age 16 and over using the SF-6D; for those younger than 16 a population norm of 0.9 21 
was assumed [15]. 22 
Adults 23 
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For adults, estimations were made for reported and non-reported disease burden which followed 1 
the same sine function as in the infants. In the peak month of 2012 the incidence in infants under 3 2 
months was 43.3 per 100,000.  Hence assuming a similar incidence in adults the estimated number 3 
of infections among the 9,569,461 women aged 20-44 in the population in the peak month was 4 
95.69*43.3 per 100,000 = 4,144. In the peak month there were 365 laboratory confirmed cases 5 
among women aged 20-44, therefore 8.8% (365/4,114) of the infections among women are believed 6 
to be laboratory confirmed.  7 
Public Health England performed a patient survey to estimate the loss in quality of life due to 8 
pertussis as well as the related health care costs [16]. Two groups of patients were recruited; 9 
laboratory confirmed cases, and coughing household contacts. The latter group is a proxy for 10 
pertussis which is not laboratory confirmed.  11 
There was a marked difference in the overall QALY loss between the two groups with 0.1 QALY for 12 
the confirmed cases and 0.04 QALY for the non-confirmed cases [16]. The health care costs were 13 
£55.55 for those confirmed and £25 for the coughing house hold contacts.  14 
Vaccine efficacy  15 
There are two licensed acellular pertussis-containing vaccines that can be used for maternal 16 
immunisation, Repevax™ and Boostrix/IPV™. Both contain low-dose diphtheria toxoid plus tetanus 17 
toxoid in combination with acellular pertussis and inactivated polio antigens but differ with respect 18 
to the number and amount of pertussis antigens each contains. Repevax™ was used for the maternal 19 
immunisation programme until July 2014  and its effectiveness estimated as 91% [1] but its efficacy 20 
as a booster dose in adults has not been evaluated. Boostrix/IPV has not been evaluated in a 21 
maternal programme but has demonstrated efficacy against laboratory-confirmed pertussis  in a 22 
randomised controlled trial in adolescents (89%, 95% CI: 19%-99%) [17]. For the purposes of this 23 
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evaluation it was therefore assumed that both booster vaccines are suitable candidates for use in a 1 
maternal programme and that the protection afforded to mother and infant by each is similar.  2 
Cost effectiveness analysis 3 
It is common practice in cost-effectiveness analysis to evaluate a supplementary strategy relative to 4 
the existing practice as baseline. Therefore the existing vaccination programme against pertussis was 5 
not re-evaluated. The analysis was performed from a health care payer’s perspective, in line with the 6 
recommendations of the National Institute of Clinical Excellence (NICE). The impact of the discount 7 
rate was investigated in 2 scenarios; discounting both QALYs and costs with 3.5%, and discounting 8 
both with 1.5%. To reflect the incorporated disease burden within the cost effectiveness analysis the 9 
discounting was applied to the estimated number of future cases. The programme was evaluated 10 
with 4 different time horizons: 5 years, 10 years, 30 years, 200 years. The assumed vaccine price was 11 
£10 or £15 plus £7.50 administration costs per dose. The uncertainty in the cost-effectiveness results 12 
were based on 1000 samples using Latin hyper cube sampling from the assigned distributions. All 13 
analysis was performed in R 2.14.1 [18] and an overview of all the used assumptions are given in 14 
table 1.  15 
For the probabilistic sensitivity analysis, distributions were assigned. To derive an average value a 16 
normal distribution was used defined by the mean and standard deviation (SD) of 1000 bootstrap 17 
samples of the original data (so to obtain an average of the mean); to derive a percentage a beta 18 
distributions was assigned so to constrain the values between 0 and 1, again based on the mean and 19 
SD of 1000 bootstrap samples of the mean. For costs inputs triangular distributions were used, with 20 
the published maximum and minimum [11] as the upper and lower quartile 21 
  22 
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Results 1 
In figure 1 the incidence in infants and women aged 20-44 is shown. As can be seen the disease 2 
between the two age groups follows a similar time course, underpinning the assumption that 3 
disease acquisition among mothers and infants is closely related, but with a time lag likely due to the 4 
later recognition and confirmation of adult compared with infant cases.  5 
The sine wave used in the model is based on the outbreak in 2012 (figure 2). In table 2 the disease 6 
burden using this model and the observed number of cases in 2012 are compared and shown to be 7 
similar, with 590 observed and 554 modelled infant cases and 15 vs 17 deaths. It should be noted 8 
that in October 2012 maternal vaccination was introduced, reducing the number of infant deaths. 9 
After introduction of the maternal programme, the peak months had an incidence of 28 per 100,000 10 
population months in infants under 3 months, and troughs of 3.5 per 100,000 population months. 11 
In the base case incidence scenario, among a vaccinated birth cohort (60% coverage), there would 12 
be an expected 1800-2000 hospitalisations (3.5% and 1.5% discounting respectively) over the first 10 13 
years after introduction, which would  include 55-60 deaths. Around 20,500 cases (3.5% discounting) 14 
would l be prevented among mothers, of which around 1800 would be severe. However, the 95% 15 
confidence interval around the 20,500 cases is 4,500 to 24,500, reflecting the wide CIs around the 16 
vaccine efficacy estimate in adults (Table 3). The annual costs of the programme are £7.3 million 17 
assuming a price of £10 per dose and £9.4 million assuming £15 per dose. See table 3 for a detailed 18 
breakdown of the gained costs and QALYs due to the maternal vaccination programme and the 19 
related incremental cost effectiveness ratio (ICER). The cost-effectiveness of the programme is 20 
driven by the prevented mortality among infants, as vaccinating only for the benefit of adults is not 21 
cost-effective.   22 
Projecting the 2010-2012 incidence into the future, with a peak every 4 years, the costs per QALY 23 
gained vary considerably depending on the discount rate, time horizon and vaccine price. Figure 3 24 
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shows the fluctuation in the price per dose in which 50% of the iterations are cost-effective (under 1 
the £20,000 threshold) over time in the base-case model. Table 4 shows the percentage of iterations 2 
in which the ICER is below a £20,000 or £30,000 cost per QALY threshold for different scenarios. 3 
When using discounting as recommended by NICE (3.5% for both costs and disease burden) in only 4 
one scenario are more than 50% of the iterations below the £30,000 threshold (5 year time horizon). 5 
Using discounting of 1.5% for costs and 1.5% for disease burden, all investigated scenarios have 6 
around 90% of the iteration below £30,000 (in case of a price of £15 this is at least 50%).  7 
The findings above are very sensitive to the modelled incidence. When the incidence in both the 8 
peak and troughs is increased by 35%, at least 88% of the iterations achieve ICERs below £30,000 9 
(3.5%/3.5% discounting and a vaccine price of £10) in all investigated time horizons, see table 5. 10 
Assuming that the incidence remains at peak level in  2012, then the programme would be highly 11 
cost effective, with an ICER of £16,865 (£12,209-£25,976; price of £10 and 3.5%/3.5% discounting). 12 
The timing of introduction of the programme influences the overall cost-effectiveness, especially for 13 
short time horizons with a higher discounting scenario, as is shown in figure 4.  14 
  15 
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Discussion 1 
Our cost effectiveness analysis shows that maternal pertussis immunisation would be highly cost 2 
effective if the peak incidence of infant disease at the time the programme was introduced, 3 
continues. However, our estimates were highly dependent on the future incidence of pertussis in 4 
infants under 3 months of age.  This is necessarily difficult to predict given the uncertainties around 5 
the reasons for the resurgence and the transmission dynamics of pertussis. Although there has been 6 
a cyclical pattern in the past, it is not as steady and clear as simulated in our model. Moreover there 7 
may be more variation in the peaks and troughs in the future, as well as in the inter-epidemic period, 8 
which up to now in the UK has remained unchanged at 3 to 4 years since the start of vaccination in 9 
the 1950s. Although the sine wave fitted the 2012 outbreak well, when using it for projecting 10 
temporal patterns in future incidence, there is necessarily considerable uncertainty about the 11 
magnitude of future peaks and troughs especially for time horizons extending many decades into the 12 
future. For shorter time horizons, the timing of the peaks in relation to the start of the programme 13 
has a major influence on cost effectiveness due to the effect of discounting.  14 
During periods of low incidence there is less direct benefit for the infant, but during periods 15 
with high incidence the benefit is considerably greater. The assumptions about future incidence in 16 
our model are therefore critical in determining cost-effectiveness. In the decade before the 2012 17 
resurgence pertussis incidence was at an all-time low in England. However there are reasons to 18 
believe that there will be a sustained elevated incidence in infants and other age groups in the 19 
future, with peaks similar to, or larger than, observed in 2012. If the resurgence seen in the UK and 20 
some other countries is associated with the shorter duration of protection of acellular vaccines then 21 
there will be more susceptible individuals in the population than in the period when whole cell 22 
vaccine was used which is likely to result in an elevated endemic incidence. There is evidence for this 23 
from the US which introduced acellular vaccines in 1997; a resurgence was first seen around 2005 24 
and an elevated endemic incidence has continued since then [19]. In England in 2014, which was  a 25 
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trough year, there was a higher than expected number of laboratory confirmed cases and deaths 1 
among infants under 3 months of age compared with the pre-resurgence trough year of 2010, 2 
having taken into account the impact of a continuing effective maternal immunisation programme 3 
(PHE). This suggests that the elevated incidence first observed in 2012 is likely to continue and be 4 
reflected in both trough and peak years.  5 
The vaccine prevents a greater number of infections in the mother than the infant. This is 6 
because the infant is only protected for 3 months compared to almost 4 years of the mother.  7 
However the disease burden is significantly greater in young infants who are at risk of death and 8 
may require invasive procedures such as ventilatory support. Therefore the prevention of pertussis 9 
in infants contributes more to the overall cost-effectiveness than prevention in the mothers. 10 
Another limiting factor related to this, the number of death due to pertussis in infants is likely to be 11 
higher due to under ascertainment leading to an even greater relative burden among infants. In 12 
adults the impact of pertussis is on the quality of life which is adversely affected by the prolonged, 13 
severe cough as it disrupts sleep and interferes with normal daily activities. The QALY loss in adults 14 
with confirmed pertussis and in their coughing household contacts was estimated during the 2012 15 
resurgence [16]. However, estimating the overall burden of pertussis in the population remains 16 
difficult. The confirmed cases for whom we have information probably represent the most severe 17 
end of the illness spectrum and therefore the distribution of patients with severe and less severe 18 
symptoms remains speculative.   19 
Due to the high efficacy of the maternal vaccination programme and the relatively high 20 
uptake of the vaccine, other approaches to prevent the disease burden in infants (in the first two 21 
months of life) have not been considered in this cost-effectiveness analysis. These include neonatal 22 
vaccination, where the new born receives a dose just after birth, and a cocooning strategy where the 23 
mother (and other household members) receives the vaccine after birth. A neonatal dose will not 24 
confer the 91% protection estimated for maternal immunisation as efficacy of single dose at around 25 
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2 months of age  is only about 50% [6]. Moreover there is an expected delay in vaccine response 1 
leaving the infant unprotected in the first two weeks of life. Therefore such a programme will be 2 
considerably less effective and therefore less cost-effective compared to a maternal programme. 3 
The cocooning strategy aims to protect the infant from exposure by proactively vaccinating likely 4 
contacts of the neonate. However, this requires the vaccination of more individuals than just the 5 
mother, and is reliant on the efficacy of the acellular pertussis vaccine against transmission of 6 
infection.  7 
Due to the periods of low incidence, the cost effectiveness of the maternal programme 8 
could be improved by switching it off at times of low incidence and on again when incidence 9 
increases. However this approach would be programmatically challenging as it would require a clear 10 
and timely trigger for the “on switch”.  While this is done with the use of antivirals for influenza, 11 
which are recommended when consultations for influenza-like-illness achieve a pre-defined rate, 12 
this would be more difficult for pertussis because of the delay between onset, disease recognition, 13 
laboratory confirmation and reporting. Furthermore for the infant to achieve the maximum benefit 14 
the optimal timing of vaccination is before the period when antibodies are actively transferred 15 
across the placenta, which is believed to commence around week 32 [20]. Therefore to make sure 16 
infants are protected at the high incidence period the programme needs to be initiated at least two 17 
months before the peak, to allow enough time for seroconversion in the mother and transfer of the 18 
antibodies. This would require a sensitive and reliable incidence-based trigger – one that preferably 19 
does not rely on an increase in infant deaths which was the trigger for the 2012 maternal 20 
immunisation programme. Also, by switching the programme off because of cost-effectiveness 21 
reasons society will have to accept that potentially preventable infant deaths will occur in the low 22 
incidence period.  23 
The cost effectiveness of the maternal programme was assessed as a supplement to the 24 
existing 4 dose paediatric programme. With the high coverage of the existing programme in England 25 
 13 
 
the incidence of disease in infants too young to be vaccinated has already been substantially 1 
reduced from the pre-vaccine era. As a result, the cost effectiveness of the maternal programme 2 
under the baseline incidence scenario was not favourable. This is despite the residual high morbidity 3 
and mortality in infants even before the recent resurgence when the annual admission rate in 4 
infants under 3 months was still over 1 per 1000 with 7 pertussis deaths per million maternities (14, 5 
18). The main objective of existing pertussis programmes is to reduce infant morbidity and mortality 6 
[9].  Had maternal vaccination been an option when national vaccination was first introduced in the 7 
1950s it may well have been the initial strategy chosen to achieve immediate infant protection with 8 
mass child hood vaccination considered later. However when introduced as an adjunct to an existing 9 
mature paediatric vaccination programme it may not appear cost effective. Our results are therefore 10 
highly context dependent and reflect the historical evolution of the UK programme.  In other 11 
settings where vaccine coverage and disease control is poorer, the incremental benefit of maternal 12 
pertussis vaccination will be greater. Its administration would be facilitated in those countries 13 
already offering tetanus vaccine in pregnancy by the development of a low priced combined 14 
acellular pertussis/tetanus vaccine.  15 
 In addition to cost-effectiveness other factors merit consideration. First, is the absolute 16 
budget impact of the programme which will be relatively inexpensive as it will cost below £10 million 17 
per year. Second, is the guaranteed protection the programme provides, compared with the 18 
uncertainties of relying on herd immunity. It therefore provides reassurance that whatever happens 19 
to the transmission of disease in the future we have an intervention in place that can protect 20 
vulnerable infants.  Third, are the wider benefits that will accrue from that programme that have not 21 
been included in the current cost-effectiveness analysis. Under the NICE guidelines, any QALY loss to 22 
care givers is not included in a cost-effectiveness analysis. Nevertheless prevention of death of a 23 
young infant prevents grief in the parents and their direct social network. Fourth, the direct 24 
protection of the mother, which will last for some years, might prevent transmission within the 25 
household on later occasions.  A recent household contact study in the Netherlands showed that 26 
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mothers played a key role in transmission of pertussis to other household members as well as her 1 
infant [8]. 2 
Other countries have used alternative strategies to control the transmission of pertussis 3 
such as a booster dose in adolescence. However the direct contact between adolescents and young 4 
infants is low [21],  hence  the impact of this programme relies on the vaccine having an impact on 5 
disease transmission and the importance of adolescents in driving the infection among people who 6 
do have contact with infants. Pertussis incidence in infants under one year of age has continued to 7 
rise despite the introduction of the adolescent booster in the US, though coverage has not been high 8 
[19]. Also vaccinating adolescents might increase the average age of infection resulting in more 9 
susceptible young mothers.  10 
In conclusion, while maternal vaccination is a highly effective intervention for preventing 11 
deaths and severe pertussis illness among young infants, its ICER as judged by standard NICE criteria 12 
may not be favourable if future incidence remains as observed in 2010-2012. However the maternal 13 
programme has a major benefit compared with the existing paediatric programme as it offers the 14 
opportunity to directly protect this highly vulnerable population, who previously could only be 15 
indirectly protected by herd immunity which has proven to be unreliable. Given the uncertainty 16 
about the ability of acellular vaccine to protect against transmission and maintain high levels of herd 17 
immunity, provision of passive protection to infants until they can develop their own active 18 
immunity through vaccination would seem prudent at least for the time being. Therefore it has been 19 
decided to keep the maternal vaccination in place in the United Kingdom for at least another 5 20 
years, and to re-evaluate  its cost-effectiveness  in the light of  the future epidemiology of pertussis 21 
[22].    22 
 23 
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Tables 1 
Table 1 Overview of all the input parameters  2 
Parameter percentage/cost Distribution Source 
Infants    
Outcome of hospitalisation    
Percentage patients no overnight 
stay  
8.3% (SD 0.0088) Beta HES 
Percentage patients requiring PICU 9.7% (SD 0.0090) Beta HES 
Percentage patients PICU with ECMO 8.3% (SD 0.0242) Beta PICAnet 
Percentage patients PICU retrieved 6.0% (SD 0.0429) Beta PICAnet 
Duration of stay not admitted to 
PICU 
5.5 days (SD 0.172) Normal HES 
Duration of stay PICU, no ECMO 6.0 days (SD 0.644) Normal PICAnet 
Duration of stay PICU, ECMO 18.1 days (SD 4.097) Normal PICAnet 
    
Costs hospitalisation    
Hospital visit without overnight stay £422 (min £282-max £523) Triangular Reference costs 
2012-2013 
PA65A 
Overnight stay hospital, no PICU £758 (min £552- max 
£885) 
Triangular Reference costs 
2012-2013  
PA65B 
Overnight stay PICU, no ECMO £2110 (min £2004- max 
£2130) 
Triangular Reference costs 
2012-2013 
 21 
 
XB04Z 
Overnight stay PICU, ECMO £4391 (min £3966 - max 
£4768) 
Triangular Reference costs 
2012-2013 
XB01Z 
Costs retrieval PICU £2799 (min £2350- max 
£3209) 
Triangular Reference costs 
2012-2013 
XB08Z 
Mortality    
Proportion died  3.1% (1.75%-4.7%) Binomial Enhanced 
surveillance 
PHE 
Utility and life years lost    
Mortality and morbidity in infants    
 Undiscounted Discounted 
1.5% 
Discounted 
3.5% 
LY lost in case of death 80.6 46.7 27.3 
QALY years lost in case of death 65.1 38.7 23.2 
QALY loss in surviving infants 0.10070 (0.00482) Normal Assumption 
    
Mothers    
Disease     
Percentage laboratory confirmed 
disease 
8.8% None See text 
Percentage non confirmed disease 20% None Assumption 
Costs    
 22 
 
Mild disease £25.63 (SD 4.81) Normal [16] 
Confirmed disease £55.55 (SD 1.59) Normal [16] 
Utility    
Mild disease  0.03645 (0.00772) Normal [16] 
Laboratory confirmed disease 0.09724 (0.0044) Normal [16] 
    
Overall Costs and Utility per case     
Infant Costs £5253 (95% CI:£4412-6126)  
Infant QALY loss discounted 1.5% 1.308 (95% CI: 0.776-1.913)  
Infant QALY loss discounted 3.5% 0.824 (95% CI: 0.504-1.188)  
Mother Costs £10.01 (95% CI: £8.1-11.85)  
Mother QALY loss 0.018 (95% CI: 0.014-0.021)  
    
Vaccine parameters    
Efficacy Infants 91% (84%-95%)  [1]  
Efficacy Mother 89% (19%-99)  [17] 
    
Price £10-£15  Assumption 
Administration costs £7.5  Assumption 
Coverage neonatal and maternal 
immunisation 
60%  Assumption 
Births England 694241  [5] 
 1 
Table 2 Outcomes of the model for a peak year (with a peak in month 8) compared to the observed 2 
number of cases and death in the year 2012. 3 
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 Observed in 2012 Model (peak year, with 
the peak in month 8) 
Hospitalisation infants 
<3 months 
590 557 
Number of deaths 15* 17 
Laboratory confirmed 
cases adult women 
aged 20-44 
2063 2669 
Non-confirmed 
pertussis cases among 
adult women aged 20-
44 
Not reported 6066 
* Maternal vaccination was introduced on October 2012 1 
 2 
Table 3 Prevented disease burden among vaccinated infants and mothers (coverage 60%) in a base 3 
case scenario with a time horizon of 10 years and 3.5% or 1.5% discounting.  4 
 Discounting Without vaccination With vaccination Increment 
Cases infants  1.5% 1,995 180 (73 – 328) 1,815 (1,667-1,922) 
3.5% 1,809 163 (67 - 297)  1,646 (1,512-1,742) 
     
Cases adults  1.5% 27,940 4,470 (0 – 22,706) 23,470 (5234-
 24 
 
27,940) 
3.5% 24,509  3,921 (0 – 19,918) 20,588 (4,591-
24,509) 
     
Costs infants 1.5% £10,483,088 
(£8,805,632-
£12,223,431) 
£942,896 (£376,107-
£1,749,613) 
£9,540,192 
(£7,855,902-
£11,266,057) 
 3.5% £9,503,345 
(£7,982,662-
£11,081,037) 
£854,774 (£340,956-
£1,586,095) 
£8,648,571 
(£7,121,694-
£10,213,137) 
Costs adults 1.5% £279,801 
(£226,295-
£330,976) 
£44,647 (£0-
£223,000) 
£235,154 (£51,454-
£321,890) 
 3.5% £245,444 
(£198,507-£ 
290,334) 
£39,164  (£0-
£195,616) 
£206,279 (£45,136-
£282,364) 
     
QALY infants  1.5% 2609 (1548-3818) 236 (77-476) 2373 (1411-3501) 
3.5% 1490 (912-2149) 135 (44-271) 1356 (8230-1967) 
QALY adults 1.5% 443  (356-533) 71 (0-365) 372 (84-505) 
3.5% 388 (310-468) 62 (0-320) 326 (73-443) 
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# Doses 1.5% 0 3,867,790 3,867,790 
 3.5% 0 3,519,464 3,519,464 
Programme costs 
(£10+£7.5) 
1.5% 0 £67,687,790 -£67,687,790 
3.5% 0 £61,590,620 -£61,590,620 
Programme costs 
(£15+£7.5) 
1.5% 0 £87,025,279 -£87,025,279 
3.5% 0 £79,187,940 -£79,187,940 
     
Vaccine price  £10+£7.5 £15+£7.5  
ICER only infants 3.5% / 3.5% £39,464 (£26,895-
£64,856) 
£52,589 (£35,871-
£85,951) 
 
1.5%/1.5% £24,783 (£16,554-
£41,710) 
£33,036 (£22,207-
£55,401) 
 
ICER only adults 3.5% / 3.5% £173267 (£138,512- 
£8,730) 
£222,956 
(£178,264£1,079,829) 
 
1.5%/1.5% £167,011 
(£133,507-
£809,498) 
£214,912 (£171,828-
£1,040,960) 
 
ICER overall 3.5% / 3.5% £31,605 (£22,834-
£48,343) 
£42,070 (£30,495-
£64,282) 
 
1.5%/1.5% £21,263 (£14,939-
£33,765) 
£28,340 (£20,045-
£44,938) 
 
 1 
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Table 4 Price per dose with 50% and 90% below the threshold, and the percentage of iterations (of a 1 
total of 1000) with an ICER under the threshold of £20,000 or £30,000 using 4 different time 2 
horizons (5 years, 10 years, 30 years and 200 years), different vaccine prices (£10 and £15 + £7.5 3 
administration costs) and discounting scenarios (3.5% costs/3.5% QALYs and 1.5% Costs /1.5% 4 
QALYs).  5 
3.5% 
Costs/3.5% 
QALYS 
5 year horizon 10 year horizon 30 year horizon 200 year horizon 
Threshold <£20,000 <£30,000 <£20,000 <£30,000 <£20,000 <£30,000 <£20,000 <£30,000 
3.5% 
Costs/3.5% 
QALYS 
        
£10+£7.5 0% 48% 0% 40% 0% 29% 0% 25% 
£15+£7.5 0% 4% 0% 2% 0% 1% 0% 1% 
1.5% 
Costs/1.5% 
QALYS 
        
£10+£7.5 46% 95% 38% 93% 26% 90% 23% 88% 
£15+£7.5 4% 69% 2% 61% 1% 50% 1% 46% 
 6 
Table 5 Price per dose with 50% and 90% below the threshold and the percentage of iterations (of a 7 
total of 1000) with an ICER below the threshold of £20,000 or £30,000 using 4 different time 8 
horizons (5 years, 10 years, 30 years and 200 years), different vaccine prices (£10 and £15 + £7.5 9 
administration costs) and scenarios with a 35% higher disease incidence. Only the discounting of 10 
3.5% costs/3.5% QALYs is shown, as this scenario was the least cost-effective.  11 
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3.5% 
Costs/3.5
% QALYS 
 5 year horizon 10 year horizon 30 year horizon 200 year horizon 
35% 
Higher 
peak/high
er low 
Threshold <£20,00
0 
<£30,00
0 
<£20,00
0 
<£30,00
0 
<£20,00
0 
<£30,00
0 
<£20,00
0 
<£30,00
0 
 £10+£7.5 39% 95% 30% 92% 20% 89% 17% 88% 
 £15+£7.5 2% 60% 1% 51% 0% 40% 0% 36% 
 1 
Figures 2 
 3 
Figure 1 Monthly incidence of hospitalised pertussis among infants (left axis) and laboratory 4 
confirmed cases among women aged 20-44 years (right axis). 5 
Figure 2 Comparison of the disease incidence model with peaks every 4 years as observed in 2012. 6 
Figure 3. The fluctuation of the cost-effective price per dose in the base-case scenario. In high 7 
incidence years the price is over £10 (3.5%/3.5% discounting), however in the low incidence years 8 
the price per dose is below £0, which means that the maximum cost per dose goes below £7.5 (the 9 
administration cost).  10 
 11 
Figure 4 The effect of an expanding time horizon on the price. Shown is the price at which 50% of the 12 
scenarios is deemed cost-effective under a threshold of £20,000 with an expanding time horizon 13 
under the two discounting scenarios. The value of 2 months, uses a time horizon of 2 months, 3 14 
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month/ 3 month etc. The profile of the first few years is highly dependent on where you start in the 1 
epidemic cycle. 2 
 3 
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